Skip to main content
. Author manuscript; available in PMC: 2016 Feb 1.
Published in final edited form as: Lancet Oncol. 2014 Jan;15(1):e42–e50. doi: 10.1016/S1470-2045(13)70334-6

Table 2.

Impact of the use of neoadjuvant therapy paired with pathologic surrogates on the expedience of clinical trials in breast cancer

Trial Disease Setting Outcome measured Time from enrollment
to publication of data
NSABP B18(56) Breast
cancers		 Neoadjuvant versus
adjuvant therapy		 Overall Survival 10 years
NSABP B-27 (59,
71) 		Breast
cancers		 Neoadjuvant therapy Overall Survival 11 years
Pathologic complete
response		 8 years
Buzdar et al (72,
73) 		HER2+
breast
cancers		 Neoadjuvant trastuzumab Overall Survival 6 years
Pathologic complete
response		 4 years
NSABP B-40 (69) Breast
cancers		 Neoadjuvant
bevacizumab		 Pathologic complete
response		 5 years
GBG44 (70) Breast
cancers		 Neoadjuvant
bevacizumab		 Pathologic complete
response		 5 years